$IRadimed (IRMD.US)$🎯 2024.4.10 Current price 42.3, positio...

New data: 23Q2, 23Q3, 23Q4. Revenue, operating profit, and net profit continued to grow.

In 2023, revenue increased 23%, operating profit increased 28.2%, net profit increased 34%, and return on net assets increased to 23.7%.

The balance ratio increased from 13.9% to 22.5%. Total assets increased, but net assets declined. Asset-side cash flow to inventory, fixed assets have increased, and debt-side payables have increased dramatically, which is a benign liability.

The current price-earnings ratio of 31.33 is not that high compared to the valuation rate, so you can still choose carefully (⭐️)